Page last updated: 2024-12-04

uridine diphosphate n-acetylgalactosamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Uridine Diphosphate N-Acetylgalactosamine: A nucleoside diphosphate sugar which serves as a source of N-acetylgalactosamine for glycoproteins, sulfatides and cerebrosides. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

UDP-N-acetyl-D-galactosamine(2-) : Dianion of UDP-N-acetyl-D-galactosamine arising from deprotonation of the diphosphate OH groups; major species at pH 7.3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

UDP-N-acetyl-D-galactosamine : A UDP-sugar having N-acetyl-D-galactosamine as the sugar component. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID46926269
CHEBI ID57847
MeSH IDM0022351

Synonyms (7)

Synonym
uridine diphosphate n-acetylgalactosamine
udp-n-acetyl-d-galactosamine
udp-n-acetyl-d-galactosamine dianion
uridine 5'-[3-(2-acetamido-2-deoxy-d-galactopyranosyl) diphosphate]
CHEBI:57847
udp-n-acetyl-d-galactosamine(2-)
Q27124999
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
nucleotide-sugar oxoanionAny nucleotide-sugar in which one or more of the diphosphate OH groups has been deprotonated.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (33)

PathwayProteinsCompounds
Metabolism14961108
Carbohydrate metabolism173120
Glycosaminoglycan metabolism3637
Chondroitin sulfate/dermatan sulfate metabolism1215
Chondroitin sulfate biosynthesis25
Metabolism of lipids500463
Sphingolipid metabolism5550
Glycosphingolipid metabolism3031
Signaling Pathways1269117
Signaling by Receptor Tyrosine Kinases29335
Signaling by FGFR477
Signaling by FGFR3217
FGFR3 ligand binding and activation44
FGFR3c ligand binding and activation34
Blood group systems biosynthesis913
ABO blood group biosynthesis36
Lewis blood group biosynthesis512
Metabolism of proteins1058144
Post-translational protein modification666112
O-linked glycosylation1919
O-linked glycosylation of mucins78
Disease1278231
Diseases of metabolism69121
Diseases of glycosylation2243
Diseases associated with glycosaminoglycan metabolism513
Defective CHSY1 causes TPBS02
Diseases associated with O-glycosylation of proteins76
Defective GALNT3 causes HFTC01
Defective GALNT12 causes CRCS101
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
Glycosphingolipid biosynthesis1316
UDP-N-acetyl-D-glucosamine biosynthesis II2333
UDP-N-acetylgalactosamine biosynthesis112

Research

Studies (161)

TimeframeStudies, This Drug (%)All Drugs %
pre-199055 (34.16)18.7374
1990's32 (19.88)18.2507
2000's43 (26.71)29.6817
2010's28 (17.39)24.3611
2020's3 (1.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (2.41%)6.00%
Case Studies1 (0.60%)4.05%
Observational0 (0.00%)0.25%
Other161 (96.99%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]